Compare Alliant Energy Corporation (LNT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Alliant Energy Corporation trades at $68.76 (market cap $17.78B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Alliant Energy Corporation is far larger — about 9.8× Recursion Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LNT | RXRX | |
|---|---|---|
Market Cap | $17.78B | $1.81B |
Sector | Utilities | Health |
52-Week High | $78.03 | $6.79 |
52-Week Low | $63.62 | $2.84 |
Enterprise Value | $29.88B | $1.33B |
Dividend Yield | 3.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
